Tailor-Made Medicine: How genomic science will lead to personalizing treatment and cures featuring discussants Steven Gutman, James Madara, Gilbert Omenn and Wayne Rosenkrans at the 2007 Aspen Health Forum. Greg Simon moderates.
Steven I. Gutman is Director of the Office of In Vitro Diagnostic Device Evaluation and Safety at the Food and Drug Administration (FDA). A board certified pathologist, Dr. Gutman has served as an FDA regulator for the past 15 years in the area of laboratory tests, referred to by the FDA as in vitro diagnostic devices. He was appointed Director of the office he now oversees in 1993, the year the office was created. Before that Dr. Gutman was Director of the FDA's Division of Clinical Laboratory Devices, where he had previously served as a medical officer.
James L. Madara, MD, is currently serving as Executive Vice President and Chief Executive Officer of the American Medical Association, Dr. Madara is an accomplished academic medical center physician, medical scientist, and administrator. He is an authority on epithelial cell biology and on gastrointestinal disease.
Gilbert S. Omenn is Professor of Medicine, Genetics, Public Health and Computational Biology at the University of Michigan, where he also serves as Director of the Center for Computational Medicine & Biology and the Proteomics Alliance for Cancer Research. From 1997 to 2002, Dr. Omenn was CEO and Executive Vice President for Medical Affairs of the University of Michigan Health System. His research interests include cancer proteomics, chemoprevention of cancers, public health genetics, science-based risk analysis, and health policy.
Among his achievements, Dr. Omenn served as Associate Director, Office of Science and Technology Policy, and Associate Director, Office of Management and Budget, in the Executive Office of the President in the Carter Administration.
Wayne A. Rosenkrans, Jr. is Scientific and Medical Strategy Director for External Medical Relations at AstraZeneca Pharmaceuticals. He is responsible for long-range strategy development supporting AstraZeneca's external scientific alliances and policy. He also is Chairman and President and a member of the board of directors of the Personalized Medicine Coalition, a Washington, D.C., based organization working with government and other agencies on evolving health policy for personalized health care. He is a recipient of the Society of Competitive Intelligence Professionals Fellows Award, and one of its former presidents.
Greg Simon is President of FasterCures/The Center for Accelerating Medical Solutions, a nonprofit, nonpartisan organization that examines the medical research and development process to discover and promote ways to speed the discovery, development and deployment of new medical treatment for today's deadly diseases.
Prior to joining FasterCures in 2003, Mr. Simon was a principal at Infotech Strategies, a Washington, D.C. consulting firm with expertise in health technology, biotech, education technology and communication technology. From 1993 to 1997, Mr. Simon was Chief Domestic Policy Advisor to Vice President Al Gore, specifically with regard to economic, science, and technology issues, and he played a leading role in a variety of related White House policies and programs.